CTOs on the Move

Marinus Pharmaceuticals

www.marinuspharma.com

 
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.marinuspharma.com
  • 5 Radnor Corporate Center 100 Matsonford Road Suite 500
    Radnor, PA USA 19087
  • Phone: 484.801.4670

Executives

Name Title Contact Details

Funding

Marinus Pharmaceuticals raised $70M on 12/13/2019

Similar Companies

Las Cumbres

EDAP TMS

EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...

Cingulate Therapeutics

Cingulate Therapeutics, LLC (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of central nervous system and neurobiological disorders.

NestleHealthScience

Nestle Health Science is pioneering a new field where nutrition becomes therapy. We are changing the course of health through research and innovation, and nutritional therapies. Visit the site to learn more.

CSL

CSL is a global biotech leader that develops and delivers life-saving medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. They have over 30,000 employees worldwide and are committed to co...